Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe most common immediate side effects of Mounjaro are gastrointestinal: nausea, loose stools, and stomach discomfort, typically appearing within hours of the first injection and settling within a few days to two weeks for most people. These early reactions are well-documented in clinical trials and in the NHS's patient information on tirzepatide. Because Mounjaro is a prescription-only medicine, a prescriber assesses your full medical picture before treatment begins — and that conversation is a good moment to set realistic expectations about what the first week or two may feel like.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
For many people, the hours after their first 2.5 mg injection pass without incident. The starting dose is deliberately low, its job is to let your digestive system acclimatise to tirzepatide rather than to produce immediate weight-loss effects. That said, the immediate side effects of Mounjaro that most people notice first are digestive: nausea, a feeling of fullness that lingers longer than usual, and sometimes loose stools or mild constipation. Burping, reflux, and a general queasiness are also commonly reported, particularly in the first 24 to 48 hours.
These effects happen because tirzepatide slows gastric emptying, food moves through the stomach more slowly, which is part of how the medicine reduces appetite. Your gut is responding to something genuinely new; a degree of protest is normal. Most people find symptoms are mildest when they eat smaller portions, avoid fatty or spicy foods in the first few days, and stay well hydrated. One practical habit worth building from day one: check in with how you feel about two hours after each injection, just to notice your pattern. Most people discover their own predictable window, which makes subsequent doses less of an unknown.
Headache, fatigue, and dizziness are also listed in clinical data and on the NHS tirzepatide page as common effects that can appear early. They are generally mild and short-lived. Injection-site redness or itching at the site (abdomen, thigh, or upper arm) is possible but tends to resolve quickly.
For the majority of people, the first week is the most noticeable. The pattern that emerges across clinical experience is: symptoms appear in the first day or two, reach their peak around days two to four, then gradually settle. By the end of the first two weeks on a given dose, most people report that GI discomfort has reduced substantially or disappeared. This cycle often repeats (at a lower intensity) when the dose is increased, because the gut is again adjusting to a new level of tirzepatide.
Understanding this pattern matters because it affects decisions. Stopping at day three because of nausea means never finding out whether day ten would have felt entirely different. Equally, if symptoms are severe, persistent beyond two weeks, or include pain rather than just discomfort, that is the prescriber's territory, not something to manage alone. The fuller side-effect picture for Mounjaro covers the range of effects across the entire treatment period, which is broader than the first-week story.
A note on timing: people sometimes find that taking their injection in the evening means any peak nausea happens overnight rather than during the working day. This is a practical adjustment worth discussing with your prescriber rather than making independently, since the injection day affects the schedule going forward.
Most of what people experience in the first days on Mounjaro is uncomfortable rather than dangerous. But a subset of symptoms warrant prompt medical attention, same day, not at the next scheduled review.
Severe, persistent stomach pain that spreads to the back, with or without vomiting, can be a sign of pancreatitis, a serious but uncommon reaction. The MHRA issued a Drug Safety Update in January 2026 specifically highlighting acute pancreatitis as a known risk with GLP-1 medicines, and flagging that patients and prescribers should be alert to it. Pancreatitis is not the same as ordinary nausea; the pain is typically much more intense and does not ease with rest or eating.
Signs of a serious allergic reaction (swelling of the face, lips, or throat, difficulty breathing, a widespread rash) also require emergency medical attention. Severe vomiting or diarrhoea that prevents you from keeping fluids down for more than a few hours carries a dehydration risk that should be assessed, not waited out. If you are on Mounjaro and have any of these symptoms, contact 111 or go to A&E; do not simply message aftercare and wait for a reply. People with questions about what is normal can also review what side effects to expect on Mounjaro for additional detail on the full spectrum of reported reactions.
The 2.5 mg starting dose generally produces the mildest immediate reactions, precisely because it was designed that way. As the dose increases (through 5 mg, 7.5 mg, and beyond) the same GI profile can re-emerge temporarily. Some people find the step from 2.5 mg to 5 mg is the most noticeable transition; others adapt smoothly. There is no reliable way to predict an individual's response, which is why prescriber-led titration matters.
What does change with experience is familiarity. People who found the first injection alarming often report that subsequent increases feel manageable because they know what to expect and when. It is also worth knowing that some people on Mounjaro experience no side effects at all, which means the arc described here does not apply to everyone. If you are considering treatment and want to understand what the side effects of Mounjaro may involve for you specifically, our prescribers discuss suitability and side effects as part of the consultation, that conversation is part of what starting your free consultation involves, not an afterthought. There is also a broader discussion of how Mounjaro works and what treatment involves for anyone still at the research stage.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.